Isomorphic Labs’ $5 billion Series C on 17 November is larger than the other 35 AI drug-discovery rounds that Cure’s 2026 funding tracker lists from January to October combined. Those 35 rounds, each $10 million or more, add up to about $3.46 billion, by our arithmetic from the tracker’s entries.
Our number: with its $2.1 billion Series B in May, Isomorphic accounts for about 67% of the $10.56 billion of 2026 AI drug-discovery rounds on that list plus the Series C, by our arithmetic. The Series C alone is about 1.45 times everyone else’s total.
Business Pill · Power Law
An evergreen Business Engineer explainer on power laws: why a few take most. It teaches the general idea only and does not discuss Isomorphic Labs or the companies in this piece.
The key insight: As we read the tracker, AI drug discovery is not one funding market but one company and a field: Isomorphic Labs accounts for about 67% of the $10.56 billion of 2026 rounds on the list plus its Series C, by our arithmetic, and its Series C alone is larger than the other 35 rounds combined.
The Next Largest Rounds of 2026
Earendil Labs, which designs biologics with AI, said on 20 March that it had raised $787 million in financing rounds, with investors including Dimension Capital, DST Global and Sanofi. It is the largest non-Isomorphic entry on the tracker.
Chai Discovery announced $400 million on 14 July “at a $3.8 billion valuation, from Index Ventures, Kleiner Perkins, Sequoia Capital, Dimension, and others.” Sequoia Capital also co-led Isomorphic’s Series C, according to Isomorphic’s release.
Enveda announced the close of a $311 million Series E on 23 September, led by Catalio Capital Management, its release says. The tracker lists Anew Labs, a ByteDance spinout, at $290 million in September, Pathos AI at $237 million and Warp Sciences at $215 million in October.

How Far Ahead Isomorphic Is
By our arithmetic, the Series C is about 6.4 times Earendil’s $787 million and 12.5 times Chai’s $400 million. Isomorphic’s release gives no valuation. Bloomberg reported on 4 November that the round would value it at about $50 billion, according to people familiar with the matter, which would be about 13 times Chai’s stated $3.8 billion.
Chai’s news page lists a $130 million Series B at a $1.3 billion valuation in December 2025, so its stated valuation rose about 2.9 times in seven months, by our arithmetic.
Earlier Rounds Outside the 2026 List
Lila Sciences says it has raised $550 million across a $200 million seed and a $350 million Series A. Xaira Therapeutics’ site lists a 23 March 2026 article titled “Xaira Therapeutics raised nearly $1 billion. Here’s its next act”.
Spending is smaller than the capital. Menlo Ventures estimates pharma discovery and research AI spend at $600 million in 2026. On 4 November we counted eight healthcare AI rounds of $20 million or more since 1 October, totalling $332.5 million, by our count.
The Structural Read
As we read the company posts, the next tier is priced in the low billions: Chai Discovery states a $3.8 billion valuation, while Bloomberg reported Isomorphic in talks at about $50 billion, roughly 13 times as much, by our arithmetic.
As we read it, some of the same investors are backing several of these companies at once: Sequoia Capital is named in Chai’s July round and co-led Isomorphic’s Series C, according to the two companies.
Chai Discovery, announcing its Series C, 14 July 2026
“In the past seven months since our Series B in December 2025, both our technical and commercial progress has accelerated.”
Three Implications
FOR AI DRUG-DISCOVERY FOUNDERS By our arithmetic, Isomorphic’s Series C is about 6.4 times Earendil’s $787 million, the largest other 2026 entry on the tracker.
FOR DRUGMAKERS Menlo Ventures estimates pharma discovery and research AI spend at $600 million in 2026, well below the capital these companies raised from investors.
RELATED Isomorphic Labs raised $5 billion in a Series C on 17 November, 2.4 times its May round.
The Business Engineer Lens
This story maps onto the Business Engineer framework The Nine Layers of AI.
The framework says: “This entire ecosystem has been shaped by constraints, bottlenecks, chokepoints, and scarcity at every layer.”
As we read it, capital is the scarce input in AI drug discovery this year, and one company holds most of it. The framework predates these rounds and does not discuss Isomorphic or drug discovery.

What Is Not Established
Cure’s tracker covers rounds of $10 million or more, is updated monthly and had no November entries when we read it, so the totals here are our sums of its entries, not a complete count of the market. The tracker marks the Warp Sciences entry as reported, and the Anew Labs amount is not confirmed by a company release we read.
We did not read the body of the Xaira article, so we do not report its details. Isomorphic, Chai, Earendil and the other companies were not contacted for this piece.
The Bottom Line
Isomorphic Labs’ $5 billion Series C is about 1.45 times the 35 other AI drug-discovery rounds Cure’s tracker lists for January to October 2026 combined, and with May’s $2.1 billion Isomorphic accounts for about 67% of the $10.56 billion total, by our arithmetic.
95,000+ executives read Business Engineer for the AI strategy frameworks cited by ChatGPT, Claude, and Perplexity.
A note on sourcing. The 2026 round list and amounts come from Cure’s AI Drug Discovery Funding Tracker 2026 (entries January to October), which we read on 17 November; we checked the Isomorphic, Earendil, Chai and Enveda amounts against the companies’ own releases or posts. Totals, shares and ratios are our arithmetic from those entries; the tracker may not list every round. The valuation report is from our earlier piece, linked. Not investment advice; for information only.
Sources: Cure AI Drug Discovery Funding Tracker 2026 · Isomorphic Labs Series C release (PDF), 17 Nov 2026 · Isomorphic Labs Series B post, 12 May 2026 · Earendil Labs release, 20 Mar 2026 · Chai Discovery Series C post, 14 Jul 2026 · Enveda release, 23 Sep 2026 · Lila Sciences Series A post · Xaira Therapeutics news page









